高速分拣大细胞的泵
|
By LabMedica International staff writers Posted on 25 Aug 2017 |

图片:微流控芯片能够以16微秒的高速分拣细胞。放大视图展示了片上分拣小眼虫细胞(图片蒙名古屋大学惠赐)。
许多医疗应用场合必须分拣单个细胞,包括从细胞悬液中分离特定的细胞类型。科研人员已经用荧光活化细胞分拣(FACS)做高通量细胞分拣。
较大细胞的FACS要求在低压下处理样本,让样本通过更宽的喷嘴,以防止损坏,因此分拣受限于低水平通量。用激光激励液滴中细胞的自体荧光或标记荧光,然后使液滴发生偏转,按照不同特性进入不同容器。因为产生的喷雾剂导致样本感染,所以这项技术引人担忧。
日本名古屋大学的科学家研究细胞分拣时用一颗微流控芯片预防样本感染。这颗芯片有微通道,将细胞悬液导入微通道进行分拣。科研小组在微流控芯片里集成了两只外部驱动的片上泵,以实现高速的流控制。他们用一只高速发动器作为泵的动力源,成功生成了一股持续16微秒的液流,进行细胞分拣。
虽然提出了各种片上细胞分拣方法,但是大细胞的高通量分拣仍受制于在大范围分拣区内控制高速液流的困难。为克服这一难题,科研小组提出把压电发动器放在微流控芯片外,用它驱动双膜泵,实现高速的局部流控制。他们评估了把液流特征换成局部流的可控性。
他们用这项技术不仅能分拣大细胞,还能分拣小细胞,而且速度快,纯度高,活力强。以100微米左右的微藻类为例测试该方法,得到95.8%的纯度、90.8%的存活率和92.8%的成功率。他们用24微米左右的癌细胞作为小细胞的模型,得到了98.9%的纯度、90.7%的存活率和97.8%的成功率。
该研究的论文发表于2017年6月14日的《芯片实验室》杂志。领衔作者、助理教授Shinya Sakuma博士说:“微流控芯片拥有十字形分拣区和有三个分支的微流控通道。主通道里的靶体/非靶体细胞在三个维度上对齐。当检测到靶细胞时,片上泵迅速启动,把细胞拣入两条兴趣通道之一。同时,把非靶细胞冲入废料通道,泵不发动。
Related Links:
名古屋大学
较大细胞的FACS要求在低压下处理样本,让样本通过更宽的喷嘴,以防止损坏,因此分拣受限于低水平通量。用激光激励液滴中细胞的自体荧光或标记荧光,然后使液滴发生偏转,按照不同特性进入不同容器。因为产生的喷雾剂导致样本感染,所以这项技术引人担忧。
日本名古屋大学的科学家研究细胞分拣时用一颗微流控芯片预防样本感染。这颗芯片有微通道,将细胞悬液导入微通道进行分拣。科研小组在微流控芯片里集成了两只外部驱动的片上泵,以实现高速的流控制。他们用一只高速发动器作为泵的动力源,成功生成了一股持续16微秒的液流,进行细胞分拣。
虽然提出了各种片上细胞分拣方法,但是大细胞的高通量分拣仍受制于在大范围分拣区内控制高速液流的困难。为克服这一难题,科研小组提出把压电发动器放在微流控芯片外,用它驱动双膜泵,实现高速的局部流控制。他们评估了把液流特征换成局部流的可控性。
他们用这项技术不仅能分拣大细胞,还能分拣小细胞,而且速度快,纯度高,活力强。以100微米左右的微藻类为例测试该方法,得到95.8%的纯度、90.8%的存活率和92.8%的成功率。他们用24微米左右的癌细胞作为小细胞的模型,得到了98.9%的纯度、90.7%的存活率和97.8%的成功率。
该研究的论文发表于2017年6月14日的《芯片实验室》杂志。领衔作者、助理教授Shinya Sakuma博士说:“微流控芯片拥有十字形分拣区和有三个分支的微流控通道。主通道里的靶体/非靶体细胞在三个维度上对齐。当检测到靶细胞时,片上泵迅速启动,把细胞拣入两条兴趣通道之一。同时,把非靶细胞冲入废料通道,泵不发动。
Related Links:
名古屋大学
Latest 实验室技术 News
Channels
Clinical Chemistry
view channel
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read moreMolecular Diagnostics
view channel
Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more
Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read moreHematology
view channel
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







